AIGIV
Pre-clinicalRecruiting 0 watching 0 views this week💤 Quiet
15
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Inhalational Anthrax
Conditions
Inhalational Anthrax
Trial Timeline
May 30, 2027 → Jul 1, 2027
NCT ID
NCT03569553About AIGIV
AIGIV is a pre-clinical stage product being developed by Emergent BioSolutions for Inhalational Anthrax. The current trial status is recruiting. This product is registered under clinical trial identifier NCT03569553. Target conditions include Inhalational Anthrax.
Hype Score Breakdown
Clinical
5
Activity
2
Company
2
Novelty
2
Community
1
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03569553 | Pre-clinical | Recruiting |
| NCT03569514 | Pre-clinical | Recruiting |
Competing Products
1 competing product in Inhalational Anthrax
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| NP-015 | Emergent BioSolutions | Phase 1 | 25 |